Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)
Fluvoxamine for Early Treatment of Covid-19: a Fully-remote, Randomized Placebo Controlled Trial
Sponsor: Covid-19 Early Treatment Fund
Listed as NCT04668950, this PHASE3 trial focuses on Coronavirus and Covid19 and remains completed. Sponsored by Covid-19 Early Treatment Fund, it has been updated 12 times since 2020, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Feb 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Feb 2022 — Nov 2022 [monthly]
Completed PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2021 — Jun 2021 [monthly]
Recruiting PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE3
-
Feb 2021 — Mar 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE3
First recorded
Dec 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Covid-19 Early Treatment Fund
- Cures Within Reach
- McGill University
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .